Rare Disease Drugs Market (2022 Edition) - Analysis By Drug Type, Therapeutic Area, Patients, Route of Administration, Distribution Channel, By Region, By Country (2022 Edition): Market Insights, and Forecast with Impact of COVID-19 (2022-2027)

Report
290 Pages
May 2022
Region: Global
Azoth Analytics
ID: 5601945

According to the research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021. The increasing focus on research activities and development of novel therapeutic drugs has facilitated the growth of the Rare Disease Drugs market. Additionally, growing product developments is leading to implementation of technologically driven innovative devices in diagnosis of rare genetic disorders.

Moreover, favorable government policies aiming at creating awareness pertaining to the Rare Disease treatment is leading to increased adoption of effective treatments of rare disorders. However, there are several factors hindering the efficient and effective clinical trials of drug development of rare disorders including low patient numbers, limited understanding of pathology and progression, and lack of established endpoints. Therefore, several regulatory bodies are engaged in implementing regulatory standards for drug approval for Rare Disease to ensure patient safety and efficacy of drugs.

Furthermore, improved detection and increased rates of diagnosis of Rare Disease are likely to contribute to rising costs. While the humanitarian benefits of Rare Disease therapies are indisputable, concerns regarding high treatment costs play a meaningful role in how payers administer and manage healthcare benefits that ultimately dictate patient access to orphan drugs. Moreover, the biological drugs are used for treating Rare Disease such as cancer with fewer side effects that have a high prevalence rate in the developed world.

Scope of the Report

The report presents the analysis of Rare Disease Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027.
The report analyses the Rare Disease Drugs Market by value (USD Billion)
The report analyses the Rare Disease Drugs Market by Drug Type (Biologics, Non-Biologics).
The report analyses the Rare Disease Drugs Market by Therapeutic Area (Infectious Disease, Oncology, Neurology, Metabolic, Others)
The report analyses the Rare Disease Drugs Market by Patients (Pediatric, Adults).
The report analyses the Rare Disease Drugs Market by Route of Administration (Oral, Injectable).
The report analyses the Rare Disease Drugs Market by Distribution Channel (Hospital & Retail Pharmacies, Online Pharmacies)..
The report analyses the Rare Disease Drugs Market by Patients (Pediatric, Adults).
The Global Knee Implants Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA)
The Global Rare Disease Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India and South Korea).
The attractiveness of the market has been presented by region, by Drug Type, by Therapeutic area, by Patients, by Route of Administration and by Distribution Channel
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies.
The companies analysed in the report include Takeda Pharmaceutical Company Limited, Sanofi, Merck KGaA, F. Hoffman-La Roche Ltd., Pfizer, Novartis AG, Bayer Group, Biogen, GlaxoSmithKline, AbbVie Inc.

Key Target Audience:

Rare Disease Drugs Manufacturers
Consulting and Advisory Firms
Government and Policy Makers
Regulatory Authorities

1. Report scope & Methodology

1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

2. Strategic Recommendations

2.1 Expand through Mergers and Acquisitions
2.2 Focus on Research and development For Rare Disease Drugs

3. Rare Disease Drugs Market: Product Outlook

4. Global Rare Disease Drugs Market: Sizing and Forecast

4.1 Global Rare Disease Drugs Market Size, By Value, Year 2017-2027
4.2 Impact of COVID-19 on Global Rare Disease Drugs Market

5. Global Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel

5.1 Competitive Scenario of Global Rare Disease Drugs Market: By Drug Type
5.1.1 Biologics - Market Size and Forecast (2017-2027)
5.1.2 Non-Biologics - Market Size and Forecast (2017-2027)
5.2 Competitive Scenario of Global Rare Disease Drugs Market: By Therapeutic Area
5.2.1 Infectious disease - Market Size and Forecast (2017-2027)
5.2.2 Oncology- Market Size and Forecast (2017-2027)
5.2.3 Neurological - Market Size and Forecast (2017-2027)
5.2.4 Metabolic - Market Size and Forecast (2017-2027)
5.2.5 Others - Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Rare Disease Drugs Market: By Patients
5.3.1 Paediatric - Market Size and Forecast (2017-2027)
5.3.2 Adults - Market Size and Forecast (2017-2027)
5.4 Competitive Scenario of Global Rare Disease Drugs Market: By Route of Administration
5.4.1 Oral - Market Size and Forecast (2017-2027)
5.4.2 Injectable - Market Size and Forecast (2017-2027)
5.5 Competitive Scenario of Global Rare Disease Drugs Market: By Distribution Channel
5.5.1 Hospitals & Retail Pharmacies- Market Size and Forecast (2017-2027)
5.5.2 Online Pharmacies - Market Size and Forecast (2017-2027)

6. Global Rare Disease Drugs Market: Regional Analysis

6.1 Competitive Scenario of Global Rare Disease Drugs Market: By Region

7. North America Rare Disease Drugs Market: An Analysis (2017-2027)

7.1 North America Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.2 North America Rare Disease Drugs Market - Prominent Companies
7.3 Market Segmentation by Drug Type (Biologics, Non-Biologics)
7.4 Market Segmentation by Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)
7.5 Market Segmentation by Patients Type (Pediatric, Adults)
7.6 Market Segmentation by Route of Administration (Oral, Injectable)
7.7 Market Segmentation by Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
7.8 North America Rare Disease Drugs Market: Country Analysis
7.9 Market Opportunity Chart of North America Rare Disease Drugs Market - By Country, By Value, 2027
7.10 Competitive Scenario of North America Rare Disease Drugs Market: By Country
7.11 United States Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.12 United States Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
7.13 Canada Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.14 Canada Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

8. Europe Rare Disease Drugs Market : An Analysis (2017-2027)

8.1 Europe Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.2 Europe Rare Disease Drugs Market - Prominent Companies
8.3 Market Segmentation by Drug Type (Biologics, Non-Biologics)
8.4 Market Segmentation by Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)
8.5 Market Segmentation by Patients Type (Pediatric, Adults)
8.6 Market Segmentation by Route of Administration (Oral, Injectable)
8.7 Market Segmentation by Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
8.8 Europe Rare Disease Drugs Market: Country Analysis
8.9 Market Opportunity Chart of Europe Rare Disease Drugs Market - By Country, By Value, 2027
8.10 Competitive Scenario of Europe Rare Disease Drugs Market: By Country
8.11 Germany Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.12 Germany Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.13 United Kingdom Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.14 United Kingdom Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.15 France Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.16 France Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.17 Italy Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.18 Italy Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

9. Asia Pacific Rare Disease Drugs Market: An Analysis (2017-2027)

9.1 Asia Pacific Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Rare Disease Drugs Market - Prominent Companies
9.3 Market Segmentation by Drug Type (Biologics, Non-Biologics)
9.4 Market Segmentation by Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)
9.5 Market Segmentation by Patients Type (Pediatric, Adults)
9.6 Market Segmentation by Route of Administration (Oral, Injectable)
9.7 Market Segmentation by Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
9.8 Asia Pacific Rare Disease Drugs Market: Country Analysis
9.9 Market Opportunity Chart of Asia Pacific Rare Disease Drugs Market - By Country, By Value, 2027
9.10 Competitive Scenario of Asia Pacific Rare Disease Drugs Market: By Country
9.11 China Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.12 China Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.13 Japan Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.14 Japan Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.15 India Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.16 India Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.17 South Korea Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.18 South Korea Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)

10. Global Rare Disease Drugs Market Dynamics

10.1 Drivers
10.2 Restraints
10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Drug Class, 2027
11.2 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Therapeutic Area, 2027
11.3 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Patients, 2027
11.4 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Route of Administration, 2027
11.5 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Distribution Channel, 2027
11.6 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Region, 2027

12. Competitive Landscape

12.1 Market Share Analysis

13. Company Analysis

13.1 Takeda Pharmaceutical Company Limited
13.2 Sanofi
13.3 Merck KGaA
13.4 F. Hoffman-La Roche Ltd.
13.5 Pfizer
13.6 Novartis AG
13.7 Bayer Group
13.8 Biogen
13.9 GlaxoSmithKline
13.10 AbbVie Inc.

14. About the Publisher

List of Figures

Global Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Prevalence of Rare Disease Drugss in the U.S., EU, and estimated prevalence in China, (In Million) 2021
World’s leading causes of death (in millions), 2018
World Population 65 Years & Above (% of Total), 2015-2019
Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Global Rare Disease Drugs - Clinical Trial
Global Rare Disease Drugs Market- By Drug Type Market Share, 2021 & 2027
Global Rare Disease Drugs Market- By Biologics, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Non-Biologics, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Therapeutic Area Market Share, 2021 & 2027
Global Rare Disease Drugs Market- By Infectious Disease, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Oncology, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Neurological, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Metabolic, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Others, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By patients Market Share, 2021 & 2027
Global Rare Disease Drugs Market- By Pediatric, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Adults, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Route of Administration Market Share, 2021 & 2027
Global Rare Disease Drugs Market- By Oral, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Injectable, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Distribution Channel Market Share, 2021 & 2027
Global Rare Disease Drugs Market- By Hospital & Retail Pharmacies, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Online Pharmacies, By Value (USD Billion), 2017-2027
Global Rare Disease Drugs Market- By Region Market Share, 2021 & 2027
North America Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
North America Prevalence of Total Cancer, 2015-2019 (In Millions)
North America Population ages 65 and above (% of total Population), 2016-2020
North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
North America Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
North America Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
North America Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
North America Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
North America Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Market Opportunity Chart of North America Rare Disease Drugs Market- By Country, By Value (Year-2027)
North America Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
United States Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
United State Prevalence of Total Cancer, 2015-2019 (In Millions)
United States Population aged 65 and above (% of total Population), 2016-2020
United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United State National Institute of Health Spending on Rare Disease Drugs, ( USD Million), 2016-2020
Median U.S. cost per patient per year for top 100 products, 2015-2018
United States Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
United States Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
United States Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
United States Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
United States Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Canada Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Canada Population aged 65 and above (% of total Population), 2016-2020
Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Canada Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Canada Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Canada Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Canada Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Canada Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Europe Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
European Countries Population ages 65 and above (% of total Population), 2020
Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Europe Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Europe Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Europe Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Europe Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Europe Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Market Opportunity Chart of Europe Rare Disease Drugs Market- By Country, By Value (Year -2027)
Europe Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Germany Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Germany Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Germany Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Germany Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Germany Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Germany Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
United Kingdom Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
United Kingdom Population ages 65 and above (% of total Population), 2016-20
United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
United Kingdom Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
United Kingdom Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
United Kingdom Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
United Kingdom Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
United Kingdom Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
France Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
France Prevalence of Total Cancer, 2015-2019 (In Millions)
France Population ages 65 and above (% of total Population), 2016-20
France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
France Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
France Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
France Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
France Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
France Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Italy Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Italy Population ages 65 and above (% of total Population), 2016-20
Italy Trend of expenditure for orphan drugs in Italy from 2016 to 2020 (In Euro USD)
Italy Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Italy Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Italy Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Italy Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Italy Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Asia Pacific Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Asia Pacific Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Asia Pacific Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Asia Pacific Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Asia Pacific Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Asia Pacific Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Market Opportunity Chart of APAC Rare Disease Drugs Market- By Country, By Value (Year -2027)
APAC Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
China Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
China Prevalence of Total Cancer, 2015-2019 (In Millions)
China Population ages 65 and above, by Countries (% of total Population), 2020
China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
China Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
China Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
China Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
China Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
China Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Japan Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Japan Population ages 65 and above (% of total Population), 2016-20
Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Japan Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Japan Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Japan Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Japan Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Japan Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
India Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
India Prevalence of Total Cancer, 2015-2019 (In Millions)
India Population ages 65 and above (% of total Population), 2016-20
India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
India Current Healthcare Expenditure per Capita, 2015-2018 (In Numbers)
E-pharmacy market in India (USD Million)
India Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
India Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
India Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
India Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
India Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
South Korea Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
South Korea Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
South Korea Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
South Korea Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
South Korea Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
South Korea Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Market Attractiveness Chart of Global Rare Disease Drugs Market- By Drug Type (Year -2027)
Market Attractiveness Chart of Global Rare Disease Drugs Market- By Therapeutic Area (Year-2027)
Market Attractiveness Chart of Global Rare Disease Drugs Market- By Patients (Year -2027)
Market Attractiveness Chart of Global Rare Disease Drugs Market- By route of Administration (Year -2027)
Market Attractiveness Chart of Global Rare Disease Drugs Market- By Distribution Channel (Year-2027)
Market Attractiveness Chart of Global Rare Disease Drugs Market- By Region (Year -2027)
Global Rare Disease Drugs company market share (%), 2020
Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Sanofi Sales Revenues, 2016-2020 (USD Million)
Sanofi Gross Profit, 2016-2020 (USD Million)
Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Merck KGaA Gross Profit, 2016-2020 (USD Million)
Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Pfizer Annual Sales Revenue (USD Million), 2016-2020
Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Pfizer sales Revenue, By Geographical Segment (%), FY2020
Novartis Annual Sales Revenue (USD Million), 2016-2020
Novartis Annual Net Income/Loss (USD Million), 2016-2020
Novartis Sales Revenue Split, By Business Segment (USD Billion), FY2020
Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Bayer Group Sales Revenues, 2016-2020 (USD Million)
Bayer Group Net Profit, 2016-2020 (USD Million)
Bayer Group, By Business Segment (%), FY2020
Bayer Group, By Geographical Segment (%), FY2020
Biogen Sales Revenues, 2016-2020 (USD Million)
Biogen Net Profit, 2016-2020 (USD Million)
Boigen, By Business Segment (%), FY2020
Biogen, By Geographical Segment (%), FY2020
GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
GlaxoSmithKline Gross Profit (USD Million), 2016-2020
GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
AbbVie Inc. Net Income (USD Million), 2016-2020
AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020

Table Information

Report Attribute	Details
No. of Pages	290
Published	May 2022
Forecast Period	2022 - 2027
Estimated Market Value ( USD ) in 2022	$ 161.5 Billion
Forecasted Market Value ( USD ) by 2027	$ 326.02 Billion
Compound Annual Growth Rate	15.0%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2346EUR$2,400USD£1,960GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€2933EUR$3,000USD£2,450GBP

Scope of the Report

Key Target Audience:

Table of Contents

Table Information

Related Topics

Related Reports

Rare Disease Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

Pharmaceutical Drugs Global Market Report 2024

Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Formulation, Age Group, Route Of Administration, End Market, Region, and Segment Forecasts, 2023-2030

Canada Pharmaceutical Market Size, Share & Trends Analysis Report By Drug Type, By Product, By Type, By Disease, By Route of Administration, By Formulation, By Age Group, By End-use, And Segment Forecasts, 2024 - 2030

Orphan Drug Growth Opportunities